Tower Research Capital (TRC)’s MIRA Pharmaceuticals MIRA Stock Holding History

Tower Research Capital (TRC)’s Portfolio MIRA Stock Details MIRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$489	Sell	517 -4,459	-90%	-$4.51K	﹤0.01%	5020
2026 Q1	$5.32K	Buy	4,976 +3,146	+172%	+$3.94K	﹤0.01%	4127
2025 Q4	$2.76K	Buy	1,830 +33	+2%	+$48	﹤0.01%	4477
2025 Q3	$2.44K	Buy	+1,797	New	+$2.61K	﹤0.01%	4630
2025 Q1	–	Sell	-6,901	Closed	-$7.87K	–	5560
2024 Q4	$7.87K	Buy	+6,901	New	+$9.01K	﹤0.01%	4034

Other funds holding MIRA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CSI

Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

FAB

First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tower Research Capital (TRC)'s MIRA Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its MIRA Pharmaceuticals (MIRA) stake by 90% in Q2 2026, selling an estimated $4.51K and leaving 517 shares worth $489. The position accounts for ﹤0.01% of the portfolio, ranked #5020.

Tower Research Capital (TRC) first reported a position in MIRA in Q4 2024 and has held it in 5 quarters since. The position peaked at $7.87K in Q4 2024. 26 funds tracked by Wall St. Rank hold MIRA as of Q2 2026.

Tower Research Capital (TRC) held 517 shares of MIRA Pharmaceuticals worth $489 as of Q2 2026.
Tower Research Capital (TRC) sold 4,459 MIRA Pharmaceuticals shares in Q2 2026, an estimated $4.51K.
MIRA Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #5020 holding.
Tower Research Capital (TRC) first reported a position in MIRA Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
Tower Research Capital (TRC)'s MIRA Pharmaceuticals position peaked at $7.87K in Q4 2024.
26 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.